needed is an army of informed patient advocates, armed with data about the
economic benefits of biosimilars and their scientifically-proven safety. Those
voices are missing.
I regret my decision to testify in support of Louisiana’s biosimilar
legislation. I was lured by the siren song of patient safety concerns. I was
uninformed about what interchangeability meant for purposes of my own
medication. I now see what legislators saw: a sympathetic and articulate law
professor who suffered from a devastating disease and took the very
medication the biosimilar state laws implicated. I was a good choice for
purposes of lobbying in favor of notification requirements.
I hope that others read this article, state lawmakers and patients alike, and
look more closely at the laws that are being sold as friendly to patients like
myself. The decision to support state biosimilar legislation must rest on much
more than a patient-friendly label and marketing campaign.